Loading...
Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis
Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizu...
Na minha lista:
| Udgivet i: | Ann Gastroenterol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Hellenic Society of Gastroenterology
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8079880/ https://ncbi.nlm.nih.gov/pubmed/33948072 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20524/aog.2021.0582 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|